Cantor Fitzgerald raised its price objective and issued an overweight rating on Progyny stock.
2 reports, 1 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald raised its price objective and issued an overweight rating on Progyny stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Progyny, Inc.
fertility benefits management company
Nothing else this week.
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald reiterated an overweight rating on BioPharma shares, reducing the target price and setting a buy rating.
- Cantor Fitzgerald raised its price target and gave an overweight rating for SOL Strategies Inc. on October 11, 2026.
- Cantor Fitzgerald raised price targets and reaffirmed ratings, while TD Cowen adjusted its ratings for Paylocity on August 7, 2026.
- Cantor Fitzgerald lowered its price target on MARA stock on October 21, 2026.
- Cantor Fitzgerald increased its price target on Eli Lilly and Company stock.
Coverage
Newest first; wire copies grouped- StockStoryProgyny (PGNY) Stock Trades Up, Here Is Why Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 3.1% in the morning session after JPMorgan raised its price target on the company's stock